Respiratory epithelial cells (EpCs) orchestrate airway mucosal inflammation in response to diverse environmental stimuli, but how distinct EpC programs are regulated remains poorly understood. Here, we report that inhalation of aeroallergens leads to expansion of airway brush cells (BrCs), specialized chemosensory EpCs and the dominant epithelial source of interleukin-25 (IL-25). BrC expansion was attenuated in mice lacking either LTC 4 synthase, the biosynthetic enzyme required for cysteinyl leukotriene (CysLT) generation, or the EpC receptor for leukotriene E 4 (LTE 4 ), CysLT 3 R. LTE 4 inhalation was sufficient to elicit CysLT 3 R-dependent BrC expansion in the murine airway through an IL-25-dependent but STAT6-independent signaling pathway. Last, blockade of IL-25 attenuated both aeroallergen and LTE 4 -elicited CysLT 3 R-dependent type 2 lung inflammation. These results demonstrate that CysLT 3 R senses the endogenously generated lipid ligand LTE 4 and regulates airway BrC number and function.
INTRODUCTION
The exogenous and endogenous cues that trigger immune responsiveness in the respiratory tract are still poorly understood. The cysteinyl leukotrienes (CysLTs) leukotriene C 4 (LTC 4 ), LTD 4 , and LTE 4 are lipid mediators recognized for their potent induction of vascular permeability, smooth muscle constriction, and cellular chemotaxis. They are synthesized by effector cells in established allergic airway inflammation (1) through the 5-lipoxygenase (5-LO)/LTC 4 synthase (LTC 4 S) pathway and elicit bronchoconstriction in asthma through activation of the type 1 cysteinyl leukotriene receptor, CysLT 1 R (2-4). However, CysLT generation is also elicited early in the primary immune response to diverse type 2 inflammatory stimuli such as the house dust mite Dermatophagoides farinae (Df ) (5), the mold Alternaria alternata (Alternaria) (6) , the helminth Nippostrongylus brasiliensis (7) , and chitin (7), a component of the fungal and arthropod cell wall. Furthermore, recent studies have suggested that CysLTs play a role in promoting the development of type 2 inflammation in the airways. CysLT 1 R conditions dendritic cells (DCs) for T helper 2 (T H 2) priming in response to house dust mite inhalation (5, 8) and augments nuclear factor of activated T cell signaling (NFAT) and type 2 cytokine generation in group 2 innate lymphoid cells (ILC2s) (7, 9, 10) , demonstrating activity to promote both innate and adaptive type 2 inflammation. LTE 4 triggers ILC2 cytokine production in vivo but is resistant to CysLT 1 R blockade (9) , indicating involvement of an additional CysLTR. Moreover, LTE 4 cannot activate ILC2s in vitro, indicating a distinct site of action (7) . Collectively, recent evidence suggests that a nonclassical CysLT receptor expressed on resident cells in the airways promotes type 2 inflammation.
CysLT 3 R (also known as OXGR1 or GPR99) is the high-affinity receptor for LTE 4 (11) . We recently determined that CysLT 3 R is expressed on murine airway epithelial cells (EpCs) and mediates goblet cell mucin release in response to exogenous LTE 4 or to endogenously generated CysLTs elicited by the fungal aeroallergen, Alternaria (6) . Furthermore, we identified a distinct role for CysLT 3 R in regulating goblet cell numbers in the nasal mucosa that was not shared by the other CysLT receptors. Thus, we hypothesized that CysLT 3 R might regulate a proximal EpC-driven inflammatory pathway important in type 2 inflammation.
EpCs orchestrate type 2 immunity at mucosal sites, in part through the production of cytokines interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP). Tuft cells, a population of chemosensory EpCs, were recently recognized as the dominant epithelial source of IL-25 in the intestine, where they control ILC2 expansion and downstream IL-13-dependent goblet cell metaplasia (12) (13) (14) . Brush cells (BrCs) are similar chemosensory EpCs in the trachea and proximal bronchi that respond to airborne irritants by activating a neural reflex and reducing the respiratory rate (15) (16) (17) . BrCs, like tuft cells, express elements of the bitter taste transduction system, including G-gustducin and transient receptor potential melastatin 5 (TRPM5) (17) , but a role for BrCs in type 2 airway inflammation has not been reported, and their numbers in the respiratory mucosa are very low at baseline. Furthermore, despite the advances in understanding chemosensory cell effector functions, the receptors that mediate chemosensory cell activation and expansion beyond taste receptors in any compartment remain largely unknown.
Here, we define the transcriptional signature of naïve airway BrCs, which express high levels of IL-25, IL-10, and IL-18 and the enzymatic pathway required for the generation of CysLTs, but express low levels of IL-33 and TSLP. We find that, in response to inhalation of common aeroallergens that elicit CysLT generation and type 2 cytokine induction, airway BrCs expand in a CysLT-dependent fashion. Of the three CysLTRs, CysLT 3 R expression is up-regulated in concert with BrC-specific genes and regulates their expansion in response to inhalation of either LTE 4 or aeroallergens. Furthermore, inhalation of LTE 4 alone is sufficient to drive BrC expansion in an IL-25-dependent but signal transducer and activator of transcription 6 (STAT6)-independent fashion, identifying an IL-13-independent pathway of airway EpC remodeling. Last, both Alternaria and LTE 4 -elicited CysLT 3 R-dependent lung inflammation required IL-25, emphasizing the importance of this BrC activation pathway for airway inflammation and remodeling and defining CysLT 3 R as an upstream regulator of BrC function.
RESULTS

BrCs are unique among airway EpCs and the dominant source of IL-25
We imaged the tracheal epithelium in whole mounts and confirmed that a population of airway EpCs in the trachea express the tuft cell markers doublecortin-like kinase 1 (DCLK1) and G-gustducin (Fig. 1A) . Airway BrCs are heterogeneous in their expression of classic BrC markers and choline acetyltransferase (ChAT) (15) . To confirm that DCLK1 marks the ChAT-expressing airway BrCs, we evaluated tracheas of ChAT BAC -eGFP (enhanced green fluorescent protein) mice (18) . In these mice, the majority of DCLK1 + cells were ChAT-eGFP + (91 ± 1%), and most ChAT-eGFP + cells were DCLK1 + (86 ± 1%), confirming that they are cholinergic chemosensory BrCs ( Fig. 1B and fig. S1A ). DCLK1 + BrCs were not immunoreactive for the ciliated EpC marker acetylated -tubulin (ACT), the secretory EpC marker club cell secretory protein (CCSP), or neuroendocrine EpC marker calcitonin gene-related peptide (CGRP; fig. S1B fig. S1D ). Airway ChAT-eGFP cells were enriched with a false discovery rate (FDR) of <0.05 for 74 of the 94 genes recently identified as a consensus intestinal tuft cell signature ( fig. S1E) (19) . Of the 20 that were not significantly enriched, no expression was detected for 6 in tracheal BrCs (Ffar3, Mlip, Smpx, Siglecf, Lect2, and Agt). When compared with EpCAM + EpCs and with CD45 + cells in the airway, principal components analysis demonstrated that BrCs grouped quite distinctly (Fig. 1D ). This BrC distinction relative to EpCAM + cells was further reflected in the notable total number of highly differentially expressed genes (Fig. 1E) . This included 1305 genes expressed at fourfold or higher levels in EpCAM + eGFP + cells (BrCs; Fig. 1E , highlighted in purple), of which 418 genes were expressed at 32-fold or higher levels in BrCs (Fig. 1E, highlighted in red) . As expected, a large number of taste receptors, their associated signal transduction system, and the acetylcholine synthesis enzymes Pld2 and Chat were enriched in BrCs (Fig. 1F) .
BrCs expressed remarkably high levels of three transcripts encoding critical enzymes of the CysLT biosynthetic pathway including Alox5 (5-LO), Alox5ap (5-LO-activating protein), and Ltc4s (LTC 4 S), as well as Pla2g4a (phospholipase A2, group IVA; Fig. 1 , F and G), suggesting that BrCs are poised to rapidly generate CysLTs in response to relevant stimuli in the airway. We confirmed that Il25 is highly enriched in BrCs and found that its receptor Il17rb is also differentially expressed in BrCs, even when compared with resident hematopoietic cells, suggesting that an autocrine loop might be operational in BrCs. Although Tslp was expressed at low levels in BrCs ( fig. S1F ), Il33 and its receptor Il1rl1 were not detected in BrCs but were expressed as expected in EpCs and hematopoietic cells, respectively (Fig. 1G) . BrCs expressed Il18, Il10, and Cxcl12 at levels similar to those of airway resident hematopoietic cells (Fig. 1G) , indicating that BrCs are poised to control airway immune responses through the production of cytokines and chemokines. These mediators were not detected in a recent report of intestinal tuft cells (19) , which might suggest a difference between chemosensory cells in the two compartments or be reflective of different sequencing approaches. Using the RIKEN database for transcriptional regulators (http://genome. gsc.riken.jp/TFdb/), we found high expression of the transcription factors Pou2f3 and Gfi1b, previously reported to control one or both chemosensory populations (Fig. 1H) (12, (20) (21) (22) . We further observed several homeobox family transcription factors (23, 24) , implicated in neural development, and high levels of Spdef, the master regulator of airway goblet cell development (25) .
Common aeroallergens induce BrC expansion in a CysLT-dependent fashion
To understand whether the airway BrC compartment might be dynamic in response to type 2 stimuli, we challenged mice with the common aeroallergen Alternaria, which induces both CysLT generation and STAT6-dependent innate immune cell activation (6, 9, 26) . After a single inhalation of Alternaria, DCLK1 + BrCs expanded in the trachea of wild-type (WT) mice as early as 3 days later and were found in clusters of two to four cells (Fig. 2, A and D −/− mice, had a trend to higher baseline numbers of BrCs that was confirmed in additional experiments (Fig. 2E ), suggesting a possible role for CysLTs in regulating BrC homeostasis. A single inhalation of the dust mite allergen Df also elicited CysLTdependent BrC expansion in the trachea by 3 days after challenge (Fig. 2E) , indicating that BrC expansion can be elicited by other allergens that induce CysLT generation (27) .
CysLT 3 R, a tracheal EpC receptor, regulates allergen-induced BrC expansion
Our previous studies in the nose had established that the early epithelial effects of CysLTs are mediated through the high-affinity LTE 4 receptor, CysLT 3 R (6). To determine the relative contributions of the three CysLT receptors to BrC expansion, we first evaluated the transcript levels of these receptors in mice challenged with phosphatebuffered saline (PBS) or Alternaria. Although all three receptors were induced by Alternaria, we noted that CysLT 3 R was highly significantly correlated to the BrC-specific transcripts Il25, Pou2f3, and Gnat3 (Fig. 3A) . In situ hybridization (ISH) revealed CysLT 3 R expression in the tracheal epithelium of naïve WT mice that was absent in the CysLT 3 R-deficient Oxgr1 −/− strain (Fig. 3B ). X-gal reactivity, marking Escherichia coli -galactosidase that was inserted in the targeted deletion of Oxgr1 (6), confirmed expression in solitary tracheal EpCs (Fig. 3C ). Immunofluorescence studies demonstrated that X-gal reactivity was detected in some, but not all, DCLK1
+ cells from Oxgr1 −/− mice ( Fig. 3D and fig. S2 ) and was also expressed in unidentified neighboring EpCs ( Fig. 3D and fig. S2 ). To evaluate a role for CysLT 3 R in regulating BrC expansion, we treated WT and CysLT 3 Rdeficient (Oxgr1 (Fig. 3 , E to G). CysLT 3 R-deficient mice had significantly higher baseline numbers of BrCs, as observed in Ltc4s −/− mice. Collectively, our data indicate that CysLT 3 R regulates aeroallergen-induced BrC expansion.
CysLT 3 R regulates BrC expansion through an IL-25-dependent but STAT6-independent pathway
To address the mechanism by which CysLT 3 R mediates BrC expansion, we administered its ligand LTE 4 intranasally on four consecutive days and assessed BrC numbers 1 day after the last inhalation. LTE 4 was sufficient to induce expansion of tracheal BrCs in WT mice, as demonstrated by increased numbers of DCLK1 + EpCs (Fig. 4, A and B ). Similar to our findings with aeroallergen inhalation, LTE 4 -elicited BrCs were often found in discrete clusters of two or three cells (Fig. 4A ). There was no LTE 4 -elicited BrC expansion or clustering in CysLT 3 R-deficient mice (Fig. 4B) (Fig. 4E) . Together, these results suggest that LTE 4 /CysLT 3 R signaling drives BrC expansion through an IL-25-dependent pathway.
CysLT 3 R regulates IL-25-dependent type 2 lung inflammation
To understand the possible sequelae of CysLT 3 R-mediated BrC activation in the lung, we looked for type 2 lung inflammation elicited by LTE 4 . Repeated inhalation of LTE 4 increased lung CD45 + cells in WT mice (Fig. 5A ) and was associated with eosinophilia, and CD4 T cell recruitment with each of these parameters was reduced in CysLT 3 (fig. S5) . Alternaria-elicited lung inflammation, eosinophilia, ILC2 cell expansion, and CD4 T cell recruitment were also reduced in CysLT 3 Rdeficient mice (Fig. 5C ) and depended on IL-25 (Fig. 5D ). There was no further reduction of Alternaria-induced inflammation in Oxgr1 −/− mice treated with IL-25 antibody, suggesting that IL-25 mediates the CysLT 3 R-dependent inflammation. Antibody blockade of IL-25 reduced but did not abolish Alternaria-elicited eosinophilia, which is likely due to the effect of IL-33, a dominant regulator of Alternariainduced ILC2 activation and type 2 inflammation (29, 30) . Collectively, these data indicate the relevance of the CysLT 3 R/BrC/IL-25 pathway to pulmonary inflammation elicited by fungal aeroallergens.
DISCUSSION
BrCs are sentinel EpCs, classified heretofore as "chemosensory" with the expression of bitter taste receptors and the capacity to activate neural sensory circuits. Here, we identify LTE 4 as a previously unrecognized driver of BrC expansion and subsequent IL-25-dependent inflammation, mediated through CysLT 3 R. These findings indicate that LTE 4 -activated BrCs have potent immune effector functions, which was unexpected given the rarity of this cell type in the respiratory mucosa. Moreover, we find that this system can be activated by several common aeroallergens that elicit endogenous CysLT generation through distinct pathways in DCs (5), mast cells (6), and possibly BrCs themselves (Fig. 1) . Thus, CysLT-dependent BrC activation allows for a conserved EpC response to diverse luminal antigens that extend beyond agonists of the bitter taste receptor system. Because significant levels of CysLTs and IL-25 are generated in response to respiratory viral infection (31-35), our results identify a ligand and receptor pair that may fine-tune BrC reactivity to the broader airway microenvironment. A remarkable finding in our study is the extent to which BrCs are distinct from other EpCs and from resident immune cells in the airway mucosa, likely reflecting their unique development in association with the neuron sensory system. Our RNA-seq data set demonstrates widespread expression of transcriptional regulators including the Hoxa family, with critical roles in spatiotemporal embryonic patterning and shaping neural synaptic circuits (23, 24) . With regard to their immune functions, we would highlight that, in addition to Il25, BrCs express high levels of transcripts encoding IL-18, important in eliciting interferon- and patterning T H 1 immunity (36); C-X-C motif chemokine ligand 12 (CXCL12)/stromal cell-derived factor 1, important in lymphocyte recruitment and activation (37); and IL-10, with immunoregulatory roles (38) . Given the broad expression of activating taste receptors on BrCs, future studies that determine the selectivity of generation of these mediators in response to diverse agonists will be of central interest. We did observe mediators (IL-10, IL-18, and CXCL12) and transcriptional regulators (Sox and Hox family transcription factors) that were not identified in intestinal tuft cells (19) . Whether this relates to chemosensory cell diversity or the lower sensitivity of single-cell analysis remains to be seen.
We found that murine airway BrCs can expand through a STAT6-independent pathway elicited by LTE 4 . Whereas the pathways driving BrC expansion in the airways were previously unknown, a well-established STAT6-and ILC2-dependent feed-forward loop is required for the expansion of the chemosensory tuft cell compartment in the intestine. Tuft cell-derived IL-25 induces the activation of ILC2s for generation of IL-13, which, in turn, activates a STAT6-dependent EpC progenitor to differentiate into tuft cells (12) (13) (14) . Our findings suggest that a similar STAT6-dependent pathway can contribute to BrC expansion triggered by Alternaria inhalation, but that it is not required with repeated inhalation of LTE 4 , likely reflecting a distinct pathway for IL-25 generation and autocrine BrC expansion driven by LTE 4 (fig. S5 ). Although further study is required to determine whether IL-13 and LTE 4 act at different stages of BrC development, our findings for LTE 4 -induced STAT6-independent BrC expansion give a clue as to how EpC remodeling, frequently regarded as a downstream product of type 2 inflammation, can develop independently from canonical IL-13 signaling.
Our study raises several questions that remain unanswered. BrCs can directly activate cholinergic sensory neurons, but whether LTE 4 or endogenously generated CysLTs can trigger the neural sensory network and attendant functions that BrCs are so poised to regulate (15, 16, 39) remains to be elucidated. In addition, whereas we find CysLT 3 R expression in the upper (6) and lower airways to be restricted to the epithelium, only a subset of BrCs express CysLT 3 R; interestingly, uncharacterized cells directly adjacent to BrCs are also positive for CysLT 3 R. Although this may be explained by the significant heterogeneity reported in both BrCs and intestinal tuft populations (16, 40) , we do note that BrCs express high levels of the stem cell marker Lgr5, raising the possibility that CysLT 3 R might specifically regulate both BrCs and their lineage-negative immediate precursors.
Structural changes in the airways, termed airway remodeling, are a recognized feature of asthma and other chronic inflammatory airway diseases. Although murine tracheal BrCs are a relatively static population in the naïve state (41), here we detected both allergenand LTE 4 -elicited BrC expansion as early as day 3 in the trachea, indicating that some changes in EpC composition can occur quite rapidly. Whether these newly developed DCLK1
+ cells have the capacity to produce lipid mediators and cytokines and activate the cholinergic sensory system remains to be elucidated. However, we did find that rapid BrC expansion was linked to the capacity to generate IL-25 and IL-25-dependent lung inflammation. Thus, CysLT 3 Rdriven BrC expansion is an early feature of EpC remodeling that can both shape airway inflammation and confer enhanced recognition of inhaled allergens, pathogens, or commensal organisms.
Last, LTE 4 is generated in the setting of viral exacerbations of asthma (42) and in infants with no preceding lung disease (31) (32) (33) (34) , suggesting that CysLT generation is integral to the innate immune response in human airways. LTE 4 alone is sufficient to induce eosinophilia in asthmatics (43) that is independent of CysLT 1 R blockade (4). Thus, uncovering a previously unappreciated function for CysLT 3 R in directing an EpC program to expand and activate BrCs could have significant pathobiologic and therapeutic implications for a range of human lung diseases.
MATERIALS AND METHODS
Study design
The aim of this study was to define the role of LTE 4 and its receptor, CysLT 3 R, in aerollergen-driven BrC expansion and IL-25-dependent type 2 immunity. We characterized the transcriptional profile of murine tracheal BrCs compared with other EpCs using low-input RNA-seq on sorted cells from a fluorescent BrC reporter mouse. To delineate the contribution of LTE 4 to BrC expansion and BrCderived IL-25-dependent type 2 inflammation, we characterized two murine models of aeroallergen-induced innate inflammation (Df and Alternaria) and a pharmacologic model with LTE 4 inhalation in strains lacking the enzyme required for CysLT generation or lacking CysLT 3 R.
Experimental model and mice
] mice were obtained from the National Institutes of Health Knock-Out Mouse Project (KOMP) and intercrossed to obtain Oxgr1 −/− mice (11). Ltc4s −/− mice were generated on a 129Sv background (44) and backcrossed for 15 generations onto the C57BL/6 background. WT littermates from the intercrossing of Oxgr1 −/− and Ltc4s −/− or age-and sex-matched C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were used as controls.
Cg-Tg(RP23-268L19-EGFP)2Mik/J], and WT C57BL/6J controls were purchased from the Jackson Laboratory (Bar Harbor, ME). Il25 F25/F25 mice were generated as described previously (14) . Mice were bred and housed in a specific pathogen-free facility at the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and University of Washington; pups were weaned between 19 and 28 days old. Purchased mice were used for experiments after at least 4 weeks in the same mouse facility. Male and female mice 3 to 8 months of age were used. All mice were housed in groups of four to five mice per cage with a standard 12-hour light, 12-hour dark cycle and provided food and water ad libitum. All experiments were performed during the day. The use of mice for these studies was in accordance with review and approval by the Animal Care and Use Committee of the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and University of Washington.
Aeroallergen and LTE 4 challenge protocols
Mice received a single intranasal application of 30 g of Alternaria alternata culture filtrate (lot no. 151774) or 100 g of Df extract (lot no. 245566; Greer Laboratories, Lenoir, NC) after anesthesia with an intraperitoneal injection of ketamine (10 mg/kg) and xylazine (20 mg/kg) for full sedation. The aeroallergen extracts were delivered in a total volume of 20 l of sterile PBS. Mice were euthanized at the indicated time points with isoflurane overdose, and tissues were harvested for histology and fixed with 4% paraformaldehyde (PFA) or digested for flow cytometry. In a separate set of experiments, 0.25 nmol of LTE 4 (Cayman Chemical, Ann Arbor, MI) was dissolved and diluted in 20 l of PBS after ethanol was evaporated and immediately administered intranasally. Mice of a given genotype were randomized to treatment dose, and challenges were performed in groups organized by genotype and treatment dose.
For IL-25 blocking experiments, mice were given an intraperitoneal injection of 100 g of IL-25 blocking antibody (Clone 35B) or immunoglobulin G1k (IgG1k) isotype antibody (both from BioLegend) 6 hours before the first challenge with Alternaria or LTE 4 , respectively, and a repeat intraperitoneal injection of the antibody or isotype control 48 hours later. Mice were euthanized at the indicated time points with isoflurane overdose, and tissues were harvested for histology and fixed with 4% PFA or digested for flow cytometry.
In situ hybridization
Paraffin sections (6 m) were prepared from perfused mouse trachea and lung, and ISH was performed using the ViewRNA ISH Tissue 1-Plex Assay Kit (Affymetrix) following the manufacturer's protocol. Briefly, samples were heated in pretreatment solution for 10 min (lung) or 20 min (trachea), followed by protease digestion for 10 min. Sections were hybridized with mouse Oxgr1 viewRNA Tissue Probe set (VB1-11300-VT, Affymetrix) for 3 hours at 40°C. After hybridization, samples were rinsed with wash buffer (Affymetrix) and amplified through two sequential hybridization steps with an amplifier diluent for 15 to 25 min each. Sections were then incubated with alkaline phosphatase-conjugated oligonucleotide in aqueous buffered solution for 15 min, and positive hybridization was detected with Fast Red substrate. Each step was followed by a rinse in wash buffer (Affymetrix kit), and counterstain was performed with Gill's hematoxylin. Visualization was performed with a Leica DM LB2 microscope equipped with a Nikon DXM 1200 camera.
Confocal microscopy of whole tracheal mounts and quantitative assessment of BrCs
After fixation with 4% PFA, tracheas were permeabilized in a PBSbased blocking buffer containing 0.1% Triton X-100 , 0.1% saponin, 3% bovine serum albumin, and 3% normal donkey serum for 3 hours (13) . Primary rabbit anti-DCLK1 antibody (Abcam) was added directly to the blocking buffer for incubation at 4°C for 48 to 72 hours. Tracheas were rinsed with PBS containing 0.1% Triton X-100 for 3 to 4 hours, immunoreactivity to DCLK1 was detected with secondary donkey anti-rabbit antibody conjugated to Alexa Fluor 594 (Life Technologies) after incubation for 72 hours at 4°C. Nuclear staining was performed with Hoechst 33342 nuclear stain (Sigma-Aldrich). For double-labeling experiments with CCSP, ACT, anti-GFP, and anti-CGRP antibody, the samples were incubated with both primary antibodies, followed by the appropriate secondary antibodies labeled with Alexa Fluor 488 or Alexa Fluor 594. For double-labeling experiments with rabbit anti-G-gustducin, residual rabbit immunoreactivity in DCLK1-stained tracheas was blocked for 48 hours with unlabeled donkey anti-rabbit Fab (Jackson ImmunoResearch) diluted 1:50 in blocking solution, followed by rabbit anti-G-gustducin and immunodetection with a donkey anti-rabbit (Life Technologies) for 48 to 72 hours each. For double-labeling experiments with rabbit anti-RFP in Il25 F25/F25 mice, tracheas were incubated with anti-dsRed antibody (Clontech) and visualized with Alexa Fluor 594 donkey antirabbit antibody (Life Technologies). After staining for IL-25-RFP, tracheas were rinsed overnight and residual rabbit immunoreactivity was blocked for 24 hours with rabbit serum (Thermo Invitrogen). DCLK1 immunoreactivity was detected with an Alexa Fluor 488-conjugated antibody to DCLK1 (ab 31704, provided by J. von Moltke). Tracheas were longitudinally split into two halves and embedded with the epithelial surface facing upward using a glycerol-based cover slipping solution. Images were acquired with a Zeiss LSM 700 Laser Scanning Confocal microscope with a 20× Zeiss oil, 0.8 numerical aperture (NA) objective and a 63× Zeiss oil, 1.4 NA objective. The number of BrCs for each animal was enumerated from 6 to 12 photographs corresponding to 1 to 2 mm 2 taken from the same areas of each trachea starting at the distal end in proximity to the carina. The total number of DCLK1 immunoreactive cells (ranging from 200 to 600 BrCs in unchallenged mice to 600 to 1200 BrCs in challenged mice) was divided by the area captured in the focal plane to define the number of DCLK1 + cells per square millimeter (table S2) . DCLK1 immunoreactive cells and focal plane area were evaluated using ImageJ (National Institutes of Health, Bethesda, MD). Separate images were collected for each fluorochrome and overlaid to obtain a multicolor image.
BrC isolation and sorting
For single-cell preparations, tracheas were harvested and connective tissue was removed. Tracheas were opened longitudinally and incubated in prewarmed PBS solution containing dispase (16 U/ml; Gibco) and deoxyribonuclease I (DNase I; 20 g/ml; Sigma-Aldrich) for 30 to 40 min at room temperature with gentle shaking. The first step of digestion was stopped by adding cold Dulbecco's modified Eagle's medium + 5% fetal calf serum (FCS). The tracheas were removed from the solution, and the tracheal epithelium was peeled off with a scalpel under a dissecting microscope. The epithelium was incubated with the remaining submucosa and adventitia in Hepes-Tyrode's buffer without calcium (Boston BioProducts, Boston, MA) containing 20 l of papain (28 U/mg; Sigma-Aldrich) per milliliter of buffer and 10 l l-cysteine (25 mg/ml; Sigma-Aldrich) per milliliter of buffer for 30 min at 37°C with gentle agitation. Papain digestion was terminated with Tyrode's solution (Boston BioProducts) with 2 l leupeptin (5 mg/ml; Sigma-Aldrich) per milliliter of buffer. The digested tissue was vortexed for 30 s and thoroughly triturated using a 21-gauge needle. + cells were separately sorted using monoclonal antibodies (mAbs) against CD45 and EpCAM, after dead cell exclusion with propidium iodide. Cells were sorted at the Brigham and Women's Human Immunology Flow Core using a BD FACSAria Fusion cell sorter. At least 300 but no more than 500 cells from one to two naïve or PBS-treated mouse tracheas were sorted into TCL buffer (Qiagen) supplemented with RNAprotect Cell Reagent (Qiagen).
Low-input RNA-seq
Cells from tracheal single-cell suspensions were processed at the Broad Institute Technology Labs using low-input eukaryotic Smartseq2. Briefly, Smart-seq2 libraries were sequenced on an Illumina NextSeq500 using a High Output kit to generate 2 × 25 bp reads (plus dual index reads). Each sample's sequences were aligned using STAR v2.4.2a (45) and the following parameters: --twopassMode Basic, --alignIntronMax 1000000, --alignMatesGapMax 1000000, --sjdbScore 2, --quantMode TranscriptomeSAM, and --sjdbOverhang 24. Alignments were processed using Picard v1.1073 tools to add read groups and other sequencing information, reorder the BAM file to the reference, and mark duplicate sequences. Transcripts per kilobase million (TPM) was then quantified using RSEM v1.2.21 (46) with the paired-end option. The data were assessed for quality using RNA-SeQC (47) RNA-seq data analysis Differential expression analysis of RNA-seq results was conducted using R Bioconductor. Raw counts were derived using the featureCounts function of Rsubread (48) . Count normalization and differential expression analysis were conducted using the DESeq2 package (49) . Genes were considered to be significantly differentially regulated on the basis of a fold change in expression of >4-fold and an FDR of <0.05 based on a Benjamini-Hochberg adjusted P value to correct for multiple comparisons. Principal components analysis was conducted using the top 500 differentially regulated genes by FDR.
X-gal staining X-gal staining was performed on mouse tracheas as previously described (6) . Visualization was performed in 8-m deparaffinized sections with a Leica DM LB2 microscope equipped with a Nikon DXM 1200 camera. For colocalization studies, direct visualization of X-gal-stained tissue was achieved after excitation at 633 nm and recording fluorescence emission in the 650 to 770 nm range on an LSM 700 microscope.
Flow cytometry
Lungs were perfused with 10 ml of cold Hanks' balanced salt solution (HBSS), and the right lower lobe was removed, physically dissociated with a gentleMACS Dissociator (Miltenyi Biotec, San Diego, CA) in 10 ml of RPMI 1640 containing 5% FCS, and then enzymatically dissociated with collagenase (500 U/ml; CLS-IV, Worthington Biochemical), dispase, and DNase I (0.02 mg/ml; Sigma-Aldrich) in RPMI 1640 with 5% FCS at 37°C for 30 min with agitation at 200 rpm. Single cells were harvested by adding another 10 ml of RPMI 1640 with 10% FCS and then collected by centrifugation. Cell suspensions were washed with HBSS and prepared for analysis by flow cytometry. Nonspecific mAb uptake was blocked with CD16/32 (2.4G2; BD Biosciences) for at least 30 min, and appropriate mAb was added for 30 min, followed by Hoechst 33342 for dead cell exclusion. Eosinophils were identified as CD45/CD11b/SiglecF + cells with high side scatter that were negative for CD11c and major histocompatibility complex II (MHC II; fig. S3A ). DCs were identified as SiglecF 
Reverse transcription polymerase chain reaction
Whole tracheas and lungs were harvested after mice were bled through the abdominal aorta. Total RNA was isolated with TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol and further purified with the RNeasy Micro Kit (Qiagen). Total RNA (1 g) was reverse-transcribed with SuperScript III (Invitrogen), and quantitative reverse transcription polymerase chain reaction (PCR) was performed with primers specific for mouse Oxgr1, Cysltr1, Gnat3, Il25, Pou2f3, or 18S ribosomal RNA (rRNA; Qiagen) or Cysltr2 (Sigma-Aldrich) using Brilliant II SYBR Green QPCR Master Mix with Low ROX and amplification with the Mx3005P Real-Time PCR System (Agilent Technologies, Santa Clara, CA) under the following conditions: 98°C for 15 s, 60°C for 30 s, 40 cycles. The ratio of each mRNA relative to the 18S rRNA was calculated with the C t method.
Statistics
Analysis was performed with GraphPad Prism software (version 5.01, GraphPad, La Jolla, CA). Nonparametric two-sided Mann-Whitney tests were used to determine significance in pairwise comparison of responses in the in vivo models. Data indicate means ± SEMs in all bar graphs. Correlations were performed using linear regression and Spearman correlation. For RNA-seq analysis, hypergeometric distribution was calculated using the R stats package. P < 0.05 was considered significant. Sample sizes were not predetermined by statistical methods.
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